After hours, Cassava Sciences stock price fell sharply as FDA paused the company's epilepsy drug trial.

Cassava Sciences' stock price has fallen after the company announced that the U.S. Food and Drug Administration had placed a hold on its clinical trial for an anti-epileptic drug. The stock dropped 15% after hours on Thursday, to $2.41. As of the Thursday close, the stock had already increased by 21% this year. The FDA has issued a clinical hold on the new drug application and proposed clinical trial of simufilam by this pharmaceutical company based in Austin, Texas. Simufilam was originally intended to be tested for the treatment of epilepsy related to tuberous sclerosis. The FDA is requesting Cassava to provide further information, including more preclinical data and modifications to the trial design. Cassava has stated that they plan to address the issues pointed out by the FDA, but they no longer anticipate being able to start the clinical trial for simufilam in the first half of 2026 as originally planned.